Medpace Holdings, Inc. (MEDP) Return on Equity (ROE): 76.95%
Is Medpace Holdings, Inc.’s return on equity (ROE) high or low?
Medpace Holdings, Inc.'s return on equity (ROE) of 76.95% is 55% above its 5-year average of 49.74%, near the high end of its 5-year range (18.04%–98.27%).
As of Wednesday, June 17, 2026. 4.52% above its 12-month average of 73.63%.
MEDP Return on Equity (ROE) Chart
MEDP Average Return on Equity (ROE) Chart
MEDP Current vs Average Return on Equity (ROE) Chart
MEDP Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
76.95%
RETURN ON EQUITY (ROE) AVG TTM
73.63%
RETURN ON EQUITY (ROE) AVG 3Y
65.34%
RETURN ON EQUITY (ROE) AVG 5Y
49.74%
RETURN ON EQUITY (ROE) AVG 10Y
30.23%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+4.52%
CURRENT VS 3Y AVG
+17.77%
CURRENT VS 5Y AVG
+54.69%
CURRENT VS 10Y AVG
+154.51%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.18B | 76.95% | 73.63% | 65.34% | 49.74% |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 2.86% | 4.70% | 4.67% | 11.22% |
| Solventum Corporation (SOLV)vs › | $13.26B | 28.82% | 23.51% | 17.50% | 13.68% |
| DaVita Inc. (DVA)vs › | $13.46B | -114.70% | 329.18% | 200.63% | 164.66% |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 10.36% | 10.54% | 10.84% | 19.93% |
| Revvity, Inc. (RVTY)vs › | $11.29B | 3.35% | 3.59% | 3.35% | 7.68% |
| Baxter International Inc. (BAX)vs › | $10.57B | -18.17% | -12.46% | -8.76% | -1.37% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | -6.28% | -2.13% | 6.32% | 9.65% |
Return Analysis
ROE
77.0%
ROA
21.6%
Medpace Holdings, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Medpace Holdings, Inc. (MEDP)?
- The return on equity (ROE) for MEDP stock is 76.95%.
- Is Medpace Holdings, Inc.'s return on equity (ROE) high or low?
- Medpace Holdings, Inc.'s return on equity (ROE) of 76.95% is 55% above its 5-year average of 49.74%, near the high end of its 5-year range (18.04%–98.27%).
- What is the TTM average return on equity (ROE) for Medpace Holdings, Inc. (MEDP)?
- The TTM average return on equity (ROE) for MEDP stock is 73.63%.
- What is the 3Y average return on equity (ROE) for Medpace Holdings, Inc. (MEDP)?
- The 3Y average return on equity (ROE) for MEDP stock is 65.34%.
- What is the 5Y average return on equity (ROE) for Medpace Holdings, Inc. (MEDP)?
- The 5Y average return on equity (ROE) for MEDP stock is 49.74%.
- What is the 10Y average return on equity (ROE) for Medpace Holdings, Inc. (MEDP)?
- The 10Y average return on equity (ROE) for MEDP stock is 30.23%.
Medpace Holdings, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 98.27% |
| 2024-12-31 | 48.98% |
| 2023-12-31 | 50.60% |
| 2022-12-31 | 63.50% |
| 2021-12-31 | 19.08% |
| 2020-12-31 | 18.04% |
| 2019-12-31 | 13.83% |
| 2018-12-31 | 12.41% |
| 2017-12-31 | 7.77% |
| 2016-12-31 | 2.20% |
| 2015-12-31 | -2.10% |
| 2014-12-31 | -3.87% |
| 2013-12-31 | 0.00% |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle